Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India

[1]  G. H. Coombs,et al.  In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization , 2016, Molecular microbiology.

[2]  A. Kulshrestha,et al.  Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovani , 2014, Parasitology Research.

[3]  M. Rai,et al.  In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis. , 2013, The American journal of tropical medicine and hygiene.

[4]  Sarman Singh,et al.  Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death. , 2013, Experimental parasitology.

[5]  J. Beijnen,et al.  Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  R. Dey,et al.  A new model of progressive visceral leishmaniasis in hamsters by natural transmission via bites of vector sand flies. , 2013, The Journal of infectious diseases.

[7]  R. Madhubala,et al.  Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern , 2013, Parasitology Research.

[8]  S. Sundar,et al.  Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  S. Sundar,et al.  Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis , 2012, PLoS neglected tropical diseases.

[10]  J. Le bras,et al.  Leishmania Resistance to Miltefosine Associated with Genetic Marker , 2012, Emerging infectious diseases.

[11]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[12]  Matthew Berriman,et al.  Iterative Correction of Reference Nucleotides (iCORN) using second generation sequencing technology , 2010, Bioinform..

[13]  O. Kaneko,et al.  Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. , 2009, The American journal of tropical medicine and hygiene.

[14]  P. Leprohon,et al.  Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  S. Croft,et al.  Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. , 2007, International journal of antimicrobial agents.

[16]  O. Zerpa,et al.  Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses , 2007, The British journal of dermatology.

[17]  H. Sindermann,et al.  Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. , 2006, The American journal of tropical medicine and hygiene.

[18]  S. Croft,et al.  Miltefosine: issues to be addressed in the future. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[19]  S. Castanys,et al.  Phospholipid Translocation and Miltefosine Potency Require Both L. donovani Miltefosine Transporter and the New Protein LdRos3 in Leishmania Parasites* , 2006, Journal of Biological Chemistry.

[20]  K. Chang,et al.  Cloning, expression, and purification of a novel recombinant antigen from Leishmania donovani. , 2006, Protein expression and purification.

[21]  J. Berman.  Visceral leishmaniasis in the New World & Africa. , 2006, The Indian journal of medical research.

[22]  S. Croft,et al.  Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[23]  S. Filteau,et al.  Plasma 25-hydroxyvitamin D does not vary over the course of a malarial infection. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[24]  S. Sundar,et al.  Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. , 2005, The Lancet. Infectious diseases.

[25]  J. Berman,et al.  Advances in leishmaniasis , 2005, The Lancet.

[26]  P. Loiseau,et al.  Alteration of Fatty Acid and Sterol Metabolism in Miltefosine-Resistant Leishmania donovani Promastigotes and Consequences for Drug-Membrane Interactions , 2005, Antimicrobial Agents and Chemotherapy.

[27]  M. Chatterjee,et al.  Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis. , 2005, Parasitology international.

[28]  S. Sundar,et al.  Availability of miltefosine for the treatment of kala-azar in India. , 2005, Bulletin of the World Health Organization.

[29]  Sarman Singh,et al.  Challenges and new discoveries in the treatment of leishmaniasis , 2004, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[30]  M. Ouellette,et al.  Functional Cloning of the Miltefosine Transporter , 2003, Journal of Biological Chemistry.

[31]  G. Matlashewski,et al.  Heterologous expression of a mammalian protein tyrosine phosphatase gene in Leishmania: effect on differentiation , 2003, Molecular microbiology.

[32]  S. Croft,et al.  Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). , 2003, International journal of antimicrobial agents.

[33]  J. Nichols,et al.  Lem3p Is Essential for the Uptake and Potency of Alkylphosphocholine Drugs, Edelfosine and Miltefosine* , 2003, Journal of Biological Chemistry.

[34]  Shyam Sundar,et al.  Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. , 2002, The Lancet. Infectious diseases.

[35]  D. Ellis.  Amphotericin B: spectrum and resistance. , 2002, The Journal of antimicrobial chemotherapy.

[36]  L. Oskam,et al.  Leishmania donovani: intraspecific polymorphisms of Sudanese isolates revealed by PCR-based analyses and DNA sequencing. , 2001, Experimental parasitology.

[37]  S. Sundar,et al.  Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  J. Berman,et al.  U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  A. Pandey,et al.  Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases , 1998 .

[40]  C. P. Thakur,et al.  Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. , 1998, Annals of tropical medicine and parasitology.

[41]  S. Reed,et al.  Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. , 1995, The Journal of parasitology.